Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Bionic Eye / Retinal Prosthesis (Next-Gen) Market: Geographic Atrophy Central Vision Restoration Demand, Photovoltaic Wireless Implant Growth, and European Commercial Launch Adoption to Drive Exceptional Market Expansion Through 2035

The global Bionic Eye / Retinal Prosthesis (Next-Gen) Market is projected to expand at an exceptional CAGR of 32.1% through 2035, driven by sustained demand for central vision restoration in geographic atrophy, growing adoption of photovoltaic wireless implant technology, and continued European commercial expansion following CE marking. Given data limitations in the underlying source figures for this specific sub-segment, this brief presents the CAGR-based growth outlook without specific market size figures. The market comprises the PRIMA Bionic Vision System (Science Corporation) as the only artificial-retina system entering commercialization in 2026, with earlier-generation products including Argus II, Alpha AMS/IMS, and IRIS II serving mainly as historical competitive reference points following their discontinuation.

The market’s exceptional 32.1% CAGR reflects a landmark clinical and regulatory milestone: the pivotal PRIMAvera trial, published in the New England Journal of Medicine, found that 26 of 32 evaluable participants (81.3%) achieved clinically meaningful visual acuity improvement of at least 0.2 logMAR at 12 months, restoring functional central vision in patients previously blinded by geographic atrophy, a condition affecting more than 5 million people worldwide. As of July 2026, Science Corporation had received CE marking and launched PRIMA commercially in Europe, with the first commercial implantation expected in Germany, while the U.S. FDA approval process continues. Coverage extending across multiple implant locations, power technologies, and vision-restoration functions underscores the breadth of clinical and manufacturing infrastructure now supporting this newly commercializing category.

Executive Snapshot

How does geographic atrophy central vision restoration demand drive the bionic eye market?
Retinal surgery centers and ophthalmology hospitals continue to evaluate PRIMA for geographic atrophy, given pivotal trial results showing 81.3% of evaluable participants achieved clinically meaningful visual acuity improvement at 12 months, establishing this indication as the primary commercial driver for the category. As geographic atrophy affects an estimated more than 5 million people worldwide, procurement associated with central vision restoration is expected to remain the dominant category through the forecast period.

What role does photovoltaic wireless implant growth play in market expansion?
Biopharmaceutical and device developers continue to advance photovoltaic implant technology, powered by near-infrared light projected from specialized glasses rather than a conventional implanted battery, sustaining structured demand from developers pursuing this differentiated design that simplifies implantation and reduces surgical and postoperative risk relative to wired retinal implants.

How does European commercial launch adoption sustain market growth?
Retinal surgery centers continue to prepare for PRIMA’s commercial availability in Europe following Science Corporation’s July 2026 CE marking, with the first commercial implantation expected in Germany, sustaining structured demand from developers and treatment centers pursuing this initial regional commercial foothold ahead of anticipated U.S. approval.

What is driving demand for retinal prostheses in reading and object-recognition function restoration?
Developers pursuing candidates capable of restoring functional tasks such as reading and writing, as demonstrated in PRIMAvera trial participants using the implant with its accompanying glasses, continue to extend retinal prosthesis technology beyond basic light perception, generating incremental demand among device developers pursuing improved functional visual outcomes.

How does external vision processing and AI image enhancement demand sustain the market?
Device developers continue to advance external camera and smart-glasses-based image processing incorporating digital enhancements such as zoom and contrast improvement, sustaining structured demand from developers pursuing improved functional vision beyond the raw resolution of the implant itself.

Which bionic eye and retinal prosthesis market segments are growing fastest?
The fastest-growing segments include photovoltaic subretinal implants, geographic atrophy indication applications, European and eventual U.S. commercial market entry, and AI-based external image processing technology.

Request Sample
Speak with an Analyst
Download TOC

Market Dynamics: Bionic Eye / Retinal Prosthesis (Next-Gen) Market

  • Clinical trial data snapshot sustaining the evidentiary foundation for the category’s growth outlook: The pivotal PRIMAvera trial found 81.3% (26 of 32) of evaluable participants achieved clinically meaningful visual acuity improvement at 12 months; geographic atrophy affects more than 5 million people worldwide; and Science Corporation received CE marking with commercial launch beginning in Europe as of July 2026.
  • PRIMA sustaining the entirety of current commercialization activity as the only artificial-retina system launching in 2026: This system continues to anchor the substantial majority of current bionic eye and retinal prosthesis commercial and clinical activity.
  • Geographic atrophy sustaining the leading current indication over inherited retinal disease populations: This large age-associated blindness population continues to represent PRIMA’s primary commercial opportunity, distinct from the smaller inherited retinal disease populations that dominated earlier-generation artificial-retina programs.
  • Photovoltaic, wirelessly powered implants sustaining structured demand above conventional wired retinal implant designs: Reduced surgical complexity and postoperative risk continue to differentiate this power technology from earlier-generation retinal prosthesis architectures.
  • European commercial launch sustaining an initial regional foothold ahead of anticipated U.S. regulatory approval: CE marking and the planned first commercial implantation in Germany continue to position Europe as the near-term center of commercial activity.
  • Functional vision restoration tasks including reading and writing sustaining structured demand above basic light perception: Clinical evidence supporting these higher-order visual functions continues to differentiate PRIMA from earlier-generation prostheses limited to more rudimentary visual percepts.

Market Segmentation: Bionic Eye / Retinal Prosthesis (Next-Gen) Market

By Technology
  • Subretinal retinal prosthesis
  • Epiretinal retinal prosthesis
  • Suprachoroidal retinal prosthesis
  • Intraretinal / intrascleral prosthesis
  • Optic-nerve prosthesis
  • Cortical visual prosthesis
  • Hybrid retinal-neural prosthesis
  • Photovoltaic retinal implant
  • Electronic retinal implant
  • Bioelectronic / neuroprosthetic vision systems
By Product
  • PRIMA Bionic Vision System
  • PRIMA next-generation platforms
  • Argus II / historical retinal prostheses
  • Alpha AMS / Alpha IMS
  • IRIS / IRIS II
  • Others
By Implant Location
  • Subretinal
  • Epiretinal
  • Intraretinal
  • Suprachoroidal
  • Intrascleral
  • Optic nerve
  • Visual cortex
  • Other neural pathway
By Disease
  • Geographic atrophy / dry age-related macular degeneration
  • Retinitis pigmentosa
  • Stargardt disease
  • Leber congenital amaurosis
  • Choroideremia
  • Other inherited retinal degeneration
  • Advanced retinal dystrophy
  • Outer retinal degeneration
  • Optic nerve disorders
  • Cortical blindness
  • Other irreversible blindness
By Target Neural Cell
  • Retinal ganglion cells
  • Bipolar cells
  • Horizontal cells
  • Amacrine cells
  • Surviving retinal neurons
  • Optic-nerve neurons
  • Visual-cortex neurons
By Delivery Method
  • Subretinal implantation
  • Epiretinal implantation
  • Suprachoroidal implantation
  • Intraretinal implantation
  • Intrascleral implantation
  • Optic-nerve implantation
  • Cortical implantation
  • Vitreoretinal surgery
  • Minimally invasive implantation
  • Robotic / image-guided implantation
By Treatment Objective
  • Restoration of functional vision
  • Reading ability
  • Mobility assistance
  • Object recognition
  • Facial recognition
  • Navigation
  • Independent living
  • Improved quality of life
  • Partial vision restoration
  • Expanded visual field
By Patient Type
  • Adult Patients
  • Geriatric Patients
  • Pediatric Patients
By Visual Severity
  • Severe visual impairment
  • Legal blindness
  • Profound visual impairment
  • Functional blindness
  • Central blindness
  • Near-total blindness
By Product Development Stage
  • Commercially Available Products
  • Phase III Products
  • Phase II Products
  • Phase I Products
  • Preclinical Products
By End User
  • Retinal surgery centers
  • Ophthalmology hospitals
  • Specialty eye clinics
  • Vitreoretinal centers
  • Academic medical centers
  • Neuro-ophthalmology centers
  • Rehabilitation centers
  • Vision-restoration centers
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Bionic Eye / Retinal Prosthesis (Next-Gen) Market

  1. Sustained pivotal trial validation driving continued commercial rollout across geographic atrophy indication: Demonstrated 81.3% clinically meaningful visual acuity improvement continues to support structured demand above the discretionary medical device baseline.
  2. Growing developer investment in photovoltaic wireless power technology supporting simplified surgical adoption: Reduced surgical and postoperative risk relative to wired implants continues to attract structured developer and surgeon interest.
  3. Continued European market access supporting initial regional commercial scale-up: CE marking and the planned first commercial implantation in Germany continue to support treatment center preparation for broader European rollout.
  4. Sustained clinical evidence supporting higher-order functional vision restoration broadening patient and clinician interest: Demonstrated reading and writing capability among trial participants continues to differentiate this technology from earlier-generation, more limited visual prostheses.
  5. Growing investment in AI-based external image processing supporting improved functional visual outcomes: Edge-AI enhancement, object recognition, and scene simplification continue to attract developer investment pursuing improved patient functional independence.
  6. Maturing regulatory pipeline supporting an approaching U.S. commercial launch: The ongoing FDA approval process continues to focus treatment center and payer attention on the category’s next major geographic expansion.

Regional Outlook: Bionic Eye / Retinal Prosthesis (Next-Gen) Market

  • Europe: Germany anchors the region’s initial commercial launch following Science Corporation’s July 2026 CE marking, with additional European markets expected to follow as regulatory and reimbursement pathways mature; regional retinal surgery centers continue to prepare specialized implantation capacity.
  • North America: The United States represents a substantial anticipated market pending completion of the ongoing FDA approval process, supported by extensive retinal surgery and ophthalmology hospital infrastructure; regional treatment centers continue to monitor regulatory developments closely.
  • Asia-Pacific: Japan, China, and South Korea represent some of the fastest-growing regional markets as regional ophthalmic device developers and treatment centers prepare for eventual retinal prosthesis market entry; regional treatment centers continue to invest in the specialized infrastructure required to support this expansion.
  • Latin America: Brazil and Mexico represent an emerging regional demand base as specialized ophthalmology centers begin to monitor and prepare for retinal prosthesis technology adoption; this segment is expected to follow a steady, if more gradual, growth trajectory through 2035.

Competitive Landscape: Bionic Eye / Retinal Prosthesis (Next-Gen) Market

Key Players
Science Corporation, Pixium Vision SA, Second Sight Medical Products (Vivani Medical, Inc.), Retina Implant AG, Bionic Vision Technologies Pty Ltd., Nano Retina Ltd.

  • Science Corporation [July 2026] — confirmed CE marking and the commercial launch of the PRIMA Bionic Vision System in Europe, with the company noting the first commercial implantation is expected in Germany.
  • Science Corporation [October 2025] — reported publication of the pivotal PRIMAvera trial results in the New England Journal of Medicine, showing 81.3% of evaluable participants achieved clinically meaningful visual acuity improvement at 12 months.
  • Science Corporation [March 2026] — confirmed continued progress through the U.S. FDA approval process for PRIMA, with the company noting sustained ophthalmology community interest in extending commercial availability beyond its initial European launch.

Consultant POV

The Bionic Eye / Retinal Prosthesis (Next-Gen) Market’s exceptional 32.1% CAGR outlook through 2035 is anchored in sustained geographic atrophy central vision restoration demand, growing photovoltaic wireless implant activity, and continued European commercial launch adoption, set against pivotal trial data showing 81.3% of participants achieved clinically meaningful vision improvement. Sustained clinical and manufacturing investment from companies including Science Corporation, Pixium Vision SA, and Bionic Vision Technologies Pty Ltd. confirms the Bionic Eye / Retinal Prosthesis Market will sustain exceptional growth through 2035 following its landmark European commercial launch.

Request Sample
Speak with an Analyst
Download TOC

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

More Press Releases

Speak with an Analyst

    Download TOC

      Request a Sample Report